Racial and Ethnic Disparities in Geographic Availability of Buprenorphine

J Addict Med. 2024 May-Jun;18(3):335-338. doi: 10.1097/ADM.0000000000001287.

Abstract

Objectives: Overdose mortality has risen most rapidly among racial and ethnic minority groups while buprenorphine prescribing has increased disproportionately in predominantly non-Hispanic White urban areas. To identify whether buprenorphine availability equitably meets the needs of diverse populations, we examined the differential geographic availability of buprenorphine in areas with greater concentrations of racial and ethnic minority groups.

Methods: Using IQVIA longitudinal prescription data, IQVIA OneKey data, and Microsoft Bing Maps, we calculated 2 outcome measures across the continental United States: the number of buprenorphine prescribers per 1000 residents within a 30-minute drive of a ZIP code, and the number of buprenorphine prescriptions dispensed per capita at retail pharmacies among nearby buprenorphine prescribers. We then estimated differences in these outcomes by ZIP codes' racial and ethnic minority composition and rurality with t tests.

Results: Buprenorphine prescribers per 1000 residents within a 30-minute drive decreased by 3.8 prescribers per 1000 residents in urban ZIP codes (95% confidence interval = -4.9 to -2.7) and 2.6 in rural ZIP codes (95% confidence interval = -3.0 to -2.2) whose populations consisted of ≥5% racial and ethnic minority groups. There were 45% to 55% fewer prescribers in urban areas and 62% to 79% fewer prescribers in rural areas as minority composition increased. Differences in dispensed buprenorphine per capita were similar but larger in magnitude.

Conclusions: Achieving more equitable buprenorphine access requires not only increasing the number of buprenorphine-prescribing clinicians; in urban areas with higher racial and ethnic minority group populations, it also requires efforts to promote greater buprenorphine prescribing among already prescribing clinicians.

MeSH terms

  • Buprenorphine* / supply & distribution
  • Buprenorphine* / therapeutic use
  • Ethnic and Racial Minorities / statistics & numerical data
  • Ethnicity / statistics & numerical data
  • Health Services Accessibility* / statistics & numerical data
  • Healthcare Disparities* / ethnology
  • Healthcare Disparities* / statistics & numerical data
  • Humans
  • Narcotic Antagonists* / supply & distribution
  • Narcotic Antagonists* / therapeutic use
  • Opiate Substitution Treatment / statistics & numerical data
  • Opioid-Related Disorders* / drug therapy
  • Opioid-Related Disorders* / epidemiology
  • Opioid-Related Disorders* / ethnology
  • Rural Population / statistics & numerical data
  • United States / epidemiology
  • Urban Population / statistics & numerical data
  • White / statistics & numerical data

Substances

  • Buprenorphine
  • Narcotic Antagonists